Trial Profile

A Phase 3, Multi-center, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of XW003 in Patients With T2DM Inadequately Controlled by Diet and Exercise Alone

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 16 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ecnoglutide (Primary)
Indications Type 2 diabetes mellitus
Focus Registrational; Therapeutic Use
Sponsors Sciwind Biosciences

Most Recent Events

08 May 2025 Status changed from active, no longer recruiting to completed.
06 Sep 2024 According to a Sciwind Biosciences media release, data from the study will be presented at the European Association for the Study of Diabetes (EASD) 60th Annual Meeting, to be held in Madrid, Spain, September 9 -13, 2024.
13 Jul 2023 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com